Skip to main content

Author: Customer Service

SSCP Lager Bidco AB (publ) – Interim report for third quarter 2025

Date: 28th of November 2025SSCP Lager BidCo AB (publ) – Interim report for the period 1 July – 30 September 2025. Today SSCP Lager Bidco AB (publ) published an interim report for the third quarter, the report can be downloaded on www.logent.se or via the link below. For more information, please contact:Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se or Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se This press release was published on 28-11-2025 at 14:00 CET/CEST This information is of the type that SSCP Lager BidCo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation, the Swedish Securities Markets Act and the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact persons set out...

Continue reading

Gentex Announces Fourth Quarter 2025 Cash Dividend

ZEELAND, Mich., Nov. 28, 2025 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today announced that its Board of Directors recently declared a quarterly cash dividend of $0.12 (12 cents) per share that will be payable January 21, 2026, to shareholders of record of the common stock at the close of business on January 7, 2026. About the CompanyFounded in 1974, Gentex Corporation (NASDAQ: GNTX) is a technology company that leverages its core competencies, strategic partnerships, acquisitions, and ongoing research to create market-leading positions in a variety of verticals. You can view some of the Company’s latest technology at www.gentex.com and fulldisplaymirror.com,...

Continue reading

Interim Report for the period January 1 – September 30, 2025

Nasdaq OMX Copenhagen A/S Charlottenlund November 28, 2025 Announcement no. 287 Interim Report for the period January 1 – September 30, 2025 The Board of Directors has today reviewed and adopted the attached interim report for the period January 1 to September 30, 2025.The result before value adjustments and tax for the period January 1 to September 30, 2025, showed a profit of T.EUR 480.0. The result is considered as expected.The management assessed the property value in German properties at EUR 84.5 million as of September 30, 2025, compared to EUR 91.1 million as of December 31, 2024 announced in the stock exchange announcements no. 286 of November 28, 2025.From January 1 to September 30, 2025, the property value of the Group’s investment properties decreased by gross EUR -7.1 million as mentioned above and by net EUR -6.6...

Continue reading

Interim Report for the period January 1 – September 30, 2025

Nasdaq OMX Copenhagen A/S Charlottenlund November 28, 2025 Announcement no. 287 Interim Report for the period January 1 – September 30, 2025 The Board of Directors has today reviewed and adopted the attached interim report for the period January 1 to September 30, 2025.The result before value adjustments and tax for the period January 1 to September 30, 2025, showed a profit of T.EUR 480.0. The result is considered as expected.The management assessed the property value in German properties at EUR 84.5 million as of September 30, 2025, compared to EUR 91.1 million as of December 31, 2024 announced in the stock exchange announcements no. 286 of November 28, 2025.From January 1 to September 30, 2025, the property value of the Group’s investment properties decreased by gross EUR -7.1 million as mentioned above and by net EUR -6.6...

Continue reading

FLUENT Reports Third Quarter 2025 Results

Focused on Margin Expansion, Operational Efficiency, and Strategic Market Positioning Ahead of Buffalo, New York and Rosa, Florida Premium Indoor Facility Activations in Q4 2025 TAMPA, Fla., Nov. 28, 2025 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the third quarter ended September 30, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars. Management Commentary “During the third quarter, we continued to execute on our strategic priorities with a clear focus on reversing the declining margin profile and enhancing operational efficiency across our footprint ahead of our new indoor capacity hitting retail shelves in the fourth...

Continue reading

Kane Biotech Announces Third Quarter 2025 Financial Results

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations):Total revenue for the three months ended September 30, 2025 was $8,499 compared to $1,282,698 in the three months ended September 30, 2024. The vast majority of revenue recorded in the comparative quarter was related to an animal health manufacturing agreement which terminated in Q1 2025 as well as the recognition of revyve® product revenue related to a subsequently terminated US distribution agreement.Gross profit (loss) for the third quarter of 2025 was $(5,128), compared to a gross profit of $558,754 for the third quarter of 2024. Total...

Continue reading

High Arctic Overseas Announces 2025 Third Quarter Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Nov. 28, 2025 (GLOBE NEWSWIRE) — High Arctic ‎Overseas Holdings Corp. (TSXV: HOH) (“High Arctic Overseas” or the “Corporation”) has released its third quarter 2025 financial and operating results. The unaudited condensed interim consolidated financial statements (the “Financial Statements”) and management’s discussion & analysis (“MD&A”) for the quarter ended September 30, 2025, will be available on SEDAR+ at www.sedarplus.ca. All amounts are denominated in United States dollars (“USD”), unless otherwise indicated. The common shares of the Corporation began trading on the TSXV on August 16, 2024...

Continue reading

Pet Valu Holdings Ltd. Announces Renewal of Normal Course Issuer Bid

MARKHAM, Ontario, Nov. 28, 2025 (GLOBE NEWSWIRE) — Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, announced today the acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s notice of intention to renew its normal course issuer bid (the “NCIB”). Pursuant to the NCIB, the Company may purchase for cancellation up to an aggregate of 3,449,181 common shares in the capital of the Company (the “Common Shares”), representing approximately 5% of the Company’s issued and outstanding Common Shares. As at November 19, 2025, the Company had 68,983,625 Common Shares issued and outstanding. Under the NCIB, the Company may purchase up to 34,220 of its Common Shares on the TSX during any trading day, which represents 25% of the average...

Continue reading

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2 AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC.3MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) — Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to...

Continue reading

AmanahRaya REIT Records Steady Rental Revenue Growth in Q3 FY2025 to RM19.45 Million

Kuala Lumpur, Nov. 28, 2025 (GLOBE NEWSWIRE) — AmanahRaya Real Estate Investment Trust (“AmanahRaya REIT”) announced its financial results for the third quarter ended 30 September 2025 (“Q3 FY2025”), delivering a stable performance supported by an improved rental income and a continued improvement in portfolio occupancy.AmanahRaya-Kenedix REIT Manager Sdn. Bhd. For the current quarter, ARREIT recorded rental income of RM23.10 million, representing a 22.62% year-on-year increase compared to RM18.84 million in Q3 FY2024. The Trust recorded net property income of RM14.94 million, marking a 23.52% YoY improvement from RM12.10 million previously. Borrowing costs improved to RM6.69 million, declining 5.60% YoY in line with a softer interest rate environment following Bank Negara Malaysia’s recent policy rate adjustment. On a year-to-date...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.